Viva In Vitro
Murcia
About Viva In Vitro
We redefine research and development in NLRP3 and inflammatory processes by providing cutting-edge solutions and services, with a special focus on sepsis, multiple sclerosis and other diseases. Thanks to a patented ex vivo assay that allows us to establish what has happened inside the monocyte and whether or not NLRP3-immune-paralysed, we are pioneering more accurate and easier-to-use techniques to detect ASC-specks, crucial to determine the immune status of patients and assist the medical team in prescribing the most effective treatment as soon as possible, evolving towards personalised medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $2.8M
- Funding stage: Seed
- Last round: Seed (Jul 2024)
- Website: vivaivd.com
- Phone: +34 601995952
Industries & Categories
Health Care, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/viva-in-vitro-106896 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.